<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03732768</url>
  </required_header>
  <id_info>
    <org_study_id>RAD-18-001</org_study_id>
    <secondary_id>2018-002802-29</secondary_id>
    <nct_id>NCT03732768</nct_id>
  </id_info>
  <brief_title>Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Dose, Safety and Tolerability of an Intraperitoneal α-emitting Radionuclide Therapy (Radspherin®) in Patients With Platinum Sensitive Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma With Peritoneal Carcinomatosis Following CRS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncoinvent AS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oncoinvent AS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RAD-18-001 is a First-In-Man, Dose Escaltion study conducted at 2 sites. The dose escalation&#xD;
      will be performed based on a 3 + 3 design. Increasing dose levels starting at 1 MBq will be&#xD;
      followed by 2, 4 and 7 MBq. If the highest dose level of 7 MBq is reached without Dose&#xD;
      Limiting Toxicicities (which will stop the dose escalation), this will be the recommended&#xD;
      dose for further exploration. Acceptability of up to 7 MBq gives the opportunity to explore&#xD;
      the doses of the dose escalation split into two administrations, and given as two separate&#xD;
      injections 1 week apart. Split doses of 1, 2 and 3.5 MBq will be administered as two&#xD;
      injections. Each subject will be followed until disease progression (in the abdominal&#xD;
      cavity), or for 12 months after the administration of Radspherin® (whichever comes first).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The maximum number of subjects enrolled in this study is 33.&#xD;
&#xD;
      The following number of subjects will be recruited in the different cohorts:&#xD;
&#xD;
        -  Dose escalation cohorts (Phase 1a): 3 - 24 Subjects&#xD;
&#xD;
        -  Repeated injection cohorts (Phase 1b): 3 Subjects&#xD;
&#xD;
        -  Expansion cohort: 6 Subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2020</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>3+3 dose escalation study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Dose Limiting Toxicities as assessed by CTCAE v5.0.</measure>
    <time_frame>12 months</time_frame>
    <description>To investigate safety and toxicity of Radspherin®</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>21 days</time_frame>
    <description>To determine the MTD of Radspherin®, among the four suggested doses 1, 2, 4 and 7 MBq, as a single intraperitoneal (IP) injection and two repeated IP injections following cytoreductive surgery (CRS)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Peritoneal Carcinomatosis</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Radspherin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radspherin</intervention_name>
    <description>Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days. The Sponsor will provide Radspherin® in single dose glass vial and the dose for each subject will be prepared at the site.</description>
    <arm_group_label>Radspherin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to provide written informed consent and to comply with the clinical&#xD;
             study protocol&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Histologically confirmed epithelial ovarian, fallopian tube and primary peritoneal&#xD;
             carcinoma&#xD;
&#xD;
          4. Platinum sensitive recurrences of ovarian carcinoma who are eligible for debulking&#xD;
             surgery to R0.&#xD;
&#xD;
          5. AEs recovered to at least grade 1 from the effects (excluding alopecia) of any prior&#xD;
             medical therapy for malignancy at time of first administration of Radspherin®&#xD;
&#xD;
          6. ECOG Performance Status Score of 0 - 1&#xD;
&#xD;
          7. Adequate renal function&#xD;
&#xD;
               -  Creatinine ≤ 1.8 mg/dl (159 μmol/l) and&#xD;
&#xD;
               -  calculated creatinine clearance using the Cockcroft-Gault formula ≥ 45 ml/min, or&#xD;
&#xD;
               -  measured creatinine clearance ≥ 45 ml/min&#xD;
&#xD;
          8. Adequate hepatic function&#xD;
&#xD;
               -  Serum bilirubin &lt;1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN&#xD;
&#xD;
          9. Adequate bone marrow function:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/l&#xD;
&#xD;
               -  Platelets ≥ 100 x 109/l&#xD;
&#xD;
               -  Haemoglobin ≥ 9 g/dL&#xD;
&#xD;
         10. Adequate coagulation tests: INR ≤ 1.5 x ULN&#xD;
&#xD;
         11. For females of childbearing potential, a negative pregnancy test must be documented&#xD;
             prior to enrolment&#xD;
&#xD;
         12. For females of childbearing potential who have a male partner: agreement to use two&#xD;
             adequate methods of contraception (e.g. barrier, intrauterine device, hormonal&#xD;
             implants, combined oral contraceptives or vasectomized partner), during the treatment&#xD;
             period and for at least 3 months after the last dose of IMP.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Neuroendocrine tumors, or non-epithelial ovarian cancers (e.g. germ cell tumors,&#xD;
             Sex-cord tumors)&#xD;
&#xD;
          2. Tumors of borderline malignancy&#xD;
&#xD;
          3. Other synchronous visceral metastatic lesions, symptomatic CNS metastases. Metastatic&#xD;
             lymph nodes are acceptable, except thoracic lymph nodes.&#xD;
&#xD;
          4. Pregnant or lactating (nursing) women&#xD;
&#xD;
          5. Active infections requiring antibiotics, and/or physician monitoring or recurrent&#xD;
             fever &gt;38.0 ⁰C associated with a clinical diagnosis of active infection&#xD;
&#xD;
          6. Active liver disease with positive serology for active hepatitis B, hepatitis C or&#xD;
             known HIV&#xD;
&#xD;
          7. Administration of an investigational medicinal product within 28 days, or at least 5&#xD;
             times the half-life, prior to enrolment&#xD;
&#xD;
          8. Concurrent administration of any cancer therapy other than planned study treatment&#xD;
             within 4 weeks prior to, and up to 4 weeks after the last study treatment&#xD;
&#xD;
          9. Another primary malignancy within the past 3 years (except for non-melanoma skin&#xD;
             cancer, cervical cancer in situ or in situ stage 1 synchronous endometrial cancer)&#xD;
&#xD;
         10. Concurrent congestive heart failure or prior history of New York Heart Association&#xD;
             (NYHA) class III/IV cardiac disease&#xD;
&#xD;
         11. Any condition or illness that, in the opinion of the Investigator or the medical&#xD;
             monitor, would compromise the safety of the subjects or interfere with the evaluation&#xD;
             of the safety of the IMP&#xD;
&#xD;
         12. In the Investigator's opinion not able to comply with study procedures. Any medical or&#xD;
             psychological condition that would preclude participation in the study or compromise&#xD;
             the ability to give informed consent&#xD;
&#xD;
         13. Treatment with bevacizumab (Avastin®) within 5 weeks prior to CRS&#xD;
&#xD;
         14. Known hypersensitivity to any of the excipients in the study drug&#xD;
&#xD;
         15. Persons who have been placed in an institution under an official or judicial order&#xD;
&#xD;
         16. Persons who are dependent on the sponsor financially must be excluded from&#xD;
             participation&#xD;
&#xD;
         17. Persons with active SARS-CoV-2 infection must be excluded from participation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Gender identity (Ovarian Cancer)</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Kirsti Aksnes, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Oncoinvent AS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Kirsti Aksnes, PhD</last_name>
    <phone>+47 22 18 33 05</phone>
    <email>aksnes@oncoinvent.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Øyvind S Bruland, MD PhD</last_name>
    <phone>+4797174004</phone>
    <email>osb@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Els Van Nieuwenhuysen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena Braicu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital TU Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pauline Wimberger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Norwegian Radiumhospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Wang, MD</last_name>
      <phone>+47 22934771</phone>
      <email>yun.wang@ous-hf.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

